Paul M. Barr, M.D.

Paul M. Barr, M.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester, NY 14642

Administrative: (585) 273-3258
Fax: (585) 273-1042

Professional Bio

Paul M. Barr, M.D. is an Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute.





Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at Case Western Reserve University. He subsequently completed a hematology and oncology fellowship at Case Western and now holds subspecialty certification in Internal Medicine, Hematology and Oncology.

He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.

Research Bio

Paul M. Barr, M.D. is an Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute.



Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at Case Western Reserve University. He subsequently completed a hematology and oncology fellowship at Case Western and now holds subspecialty certification in Internal Medicine, Hematology and Oncology.

He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.

Awards & Honors (National)

Lymphoma Research Foundation Clinical Investigator 2012 - 2015
NIH Loan Repayment Program Award Recipient | NIH 2011 - 2014
American Society of Hematology Clinical Research Training Institute 2009
NIH/NCI K12 Paul Calabresi Scholar | NIH | University Hospitals Case Medical Center, Case Western Resrve 2008

Awards & Honors (Local)

Wilmot Cancer Research Fellowship 2011 - 2014
John W. Harris, MD Hematology Scholar Award | Case Western Reserve University 2006 - 2007
Chief Medical Resident | Case Western Reserve University/University Hospitals 2003 - 2004

Recent Journal Articles

Showing the 5 most recent journal articles. 50 available »

2016 Sep 15
Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. "Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma." Blood. 2016 Sep 15; 128(11):1458-64. Epub 2016 Jul 25.
2016 Sep 6
Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM. "Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience." Blood. 2016 Sep 6; Epub 2016 Sep 06.
2016 Aug 25
Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O. "Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy." Blood. 2016 Aug 25; 128(8):1112-20. Epub 2016 Jul 14.
2016 Jul
Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ. "Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia." Haematologica. 2016 Jul; 101(7):e295-8. Epub 2016 May 05.
2016 Jun 10
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. "US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Jun 10; 34(17):2020-7. Epub 2016 Apr 11.

Current Appointments

Medical Director, Cancer Center Clinical Trials Office - Department of Medicine (SMD)
Associate Professor - Department of Medicine, Hematology/Oncology (SMD) - Primary
Associate Professor - Cancer Center

Specialties

Hematology - American Board of Internal Medicine
Medical Oncology - American Board of Internal Medicine
Internal Medicine - American Board of Internal Medicine

Education

MD | Medicine | Northeastern Ohio Univs Med Sch2000
BA | Zoology | Miami University-Oxford1996

Post-Doctoral Training & Residency

Fellowship in Hematology/Oncology at University Hospitals of Cleveland07/01/2004 - 06/30/2007
Residency in Internal Medicine at University Hospitals of Cleveland07/01/2001 - 06/30/2003
Internship in Internal Medicine at University Hospitals of Cleveland07/01/2000 - 06/30/2001